Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Recombinant human interleukin-3 truncated diphtheria toxin fusion protein

EU orphan designation number: EU/3/15/1563   
Active ingredient: Recombinant human interleukin-3 truncated diphtheria toxin fusion protein
Indication: Treatment of acute myeloid leukaemia
Sponsor: TMC Pharma (EU) Limited
The Black Church, St Mary's Place, Dublin DO7 P4AX, Ireland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/10/2015 Orphan designation EMA/OD/112/15 (2015)7034 of 9/10/2015
29/08/2017 Transfer of orphan designation EMA/OD/112/15/T/01 (2017)5924 of 23/08/2017
1/03/2019 Transfer of orphan designation EMA/OD/0000003921 (2019)1751 of 26/02/2019